JNJ Johnson & Johnson
Company Analysis
Latest News
J&J Beats Estimates But Shares Sink 4.3%: Can a Slimmer Company Outrun Geopolitical Drag and Earnings-Quality Questions?
Shares dropped sharply as Johnson & Johnson's Q3 report delivered a paradox: headline numbers that technically cleared the bar, but underlying details that...
🔴 Johnson & Johnson is trading 4.3% down today as Middle East conflict weighed on device sales
Johnson & Johnson is trading 4.3% down at $252.52 after its October 13 third-quarter report disappointed investors, with Middle East conflict weighing on...
Johnson & Johnson’s third quarter 2026 sales matched estimates at $25.4B while Innovative Medicine outperformed
Johnson & Johnson reported third quarter 2026 results featuring solid operational sales growth of 6.0%, driven by outperformance in its Innovative Medicine...
🔴 Johnson & Johnson is trading 3.13% down in pre-market following Q3 results
Johnson & Johnson is trading at $255.48, down 3.13% in pre-market following its Q3 earnings announcement. - Before the October 13 open, adjusted EPS was...
Johnson & Johnson Q3 2026 Earnings Preview: What Analysts Expect on October 13, 2026
Consensus estimates for Johnson & Johnson's third quarter of 2026 call for revenue of $25.40 billion and adjusted EPS of $2.66, as the stock trades near...
J&J Wins Injunction Blocking U.S. Simponi Biosimilar Launch
Johnson & Johnson’s Janssen unit secured a preliminary injunction blocking the U.S. launch of the first biosimilars for its immunology drugs Simponi and...
J&J Reports 50% Five-Year Treatment-Free Remission With CARVYKTI
Johnson & Johnson reported long-term results for CARVYKTI® (ciltacabtagene autoleucel) from the Phase 2 CARTITUDE-2 study. The findings showed that a single...
Johnson & Johnson Analysis Suggests Myeloma Combo May Normalize Mortality Risk
Johnson & Johnson released a new model-based analysis of its Phase 3 MajesTEC-3 study. The analysis suggests its combination therapy for multiple myeloma could...
J&J Hits Bipolar Goal with CAPLYTA, Reducing Symptoms Within Three Days
Johnson & Johnson reported positive topline results from a pivotal Phase 3 study of CAPLYTA (lumateperone). The trial evaluated the drug for treating manic...
🟢 Johnson & Johnson is trading 3.02% up in after-hours trading after CHMP recommended TECVAYLI expansion
Johnson & Johnson is trading 3.02% up at $278.15 in after-hours trading after the European Medicines Agency’s CHMP recommended expanding TECVAYLI approval for...
J&J's TECVAYLI Gets EU Panel Backing for Expanded Myeloma Use
Johnson & Johnson announced the CHMP recommended expanding approval for its cancer drug, TECVAYLI (teclistamab). The recommendation targets adult patients with...
Johnson & Johnson Rybrevant sets survival record for rare lung cancer
Johnson & Johnson announced final Phase 3 PAPILLON study data for its drug RYBREVANT (amivantamab-vmjw). The trial evaluated RYBREVANT combined with...
J&J Nears $20 Billion Orthopedics Sale to Apollo, Streamlining Operations
Johnson & Johnson is in advanced talks to sell its DePuy Synthes orthopedics unit to Apollo Global Management. The transaction is valued at nearly $20 billion....
Johnson & Johnson hits 52-week high, UBS raises target to $320
Johnson & Johnson shares reached a new 52-week high on Wednesday. UBS increased its price target for the stock to $320 from $280. The share price rose...
Johnson & Johnson Offsets Stelara Losses With New Drug Sales
Johnson & Johnson navigates the loss of exclusivity for its blockbuster immunology drug, Stelara. Stelara sales declined by $913 million in the second quarter...
🟢 Johnson & Johnson is trading 3.13% up today as healthcare stocks gain
Johnson & Johnson is trading at 3.13% up now at $279.69 after healthcare-sector strength. • Healthcare stocks gained 1.37% during regular trading. • No new...
Johnson & Johnson's Stelara Wins FDA Approval for Pediatric Ulcerative Colitis
The U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's Stelara (ustekinumab) injection for moderately to severely active ulcerative colitis...
Robert Olstein's fund exits Johnson & Johnson stake
Value investor Robert Olstein of Olstein Capital Management has completely sold off his firm's stake in Johnson & Johnson, according to a recent quarterly...
Johnson & Johnson's Psoriasis Pill Icotyde Gains Approval in China
China's drug regulator approved Johnson & Johnson's oral medication, Icotyde (icotrokinra), for moderate-to-severe plaque psoriasis. The approval offers a new...
Johnson & Johnson wins FDA approval for IMAAVY, first-ever rare blood treatment
Johnson & Johnson received U.S. Food and Drug Administration (FDA) approval for IMAAVY (nipocalimab-aahu) to treat warm autoimmune hemolytic anemia (wAIHA)....